Aelis Farma says IDMC clears AEF0217 Phase 2b to continue unchanged

The first safety review found no serious or severe adverse events in the Down syndrome trial, while recruitment reached 65 randomized participants out of 188 planned.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.